Clinical trial NCT05075928: Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
Official title: Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: SARS-COV-2
Keywords: SARS-COV-2
Covid-19
Antiphospholipid syndrome (APS)
autoimmune disease
antiphospholipid antibodies (aPL)
thrombosis
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-10-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment

Brief summary: SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.


Eligibility criteria: Inclusion criteria:

* Adult patient (≥18 years old)
* Patient taken care of in the SMO pole or the NHC surgical resuscitation service or hospitalized or consultant to the HUS between 01/03/2020 and 31/05/2020
* Patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment
* or Patient infected with Covid-19, with a documented infection, without documented thrombosis (arterial or venous), with in the standard work-up an increase in TCA revealing the presence of LA
* Subject having given his agreement for the reuse of his data for the purposes of this research

Exclusion criteria:

* Subject having expressed opposition to participating in the study
* Subject under guardianship or guardianship
* Subject under safeguard of justice

Primary outcomes:
measure: Retrospective study of thrombotic complications in a cohort of COVID patients with a circulating anticoagulant
timeFrame: Files analysed retrospectively from March 01, 2020 to May 31, 2019 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg
Study officials:
affiliation: Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg
name: Anne-Sophie Korganow, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: